<DOC>
	<DOCNO>NCT01080352</DOCNO>
	<brief_summary>Can high dose , intravenous Vitamin C prolong life patient metastatic prostate cancer ? Prostate cancer common cancer ( exclude skin cancer ) men Denmark Unites States . When metastatic disease present cure longer possible . The main treatment stage castration , either surgical medical , end patient testosterone production cause temporary regression disease activity . Eventually , cancer progress , usually within 2 year castration , aggressive course survival 2-3 year . The current treatment option patient , undergone castration disease progression , chemotherapy limit gain quality life survival . This clinical study phase 2 study evaluate effect high dose intravenous vitamin c subject early castration resistant prostate cancer . Primary endpoint : - Prostate specific antigen ( PSA ) change 12 20 weekly vitamin c infusion Secondary endpoint : - Bone metastasis change 12 20 weekly vitamin c infusion - Changes bone specific alkaline phosphate , oxidative DNA-damage , PINP , NTX 12 20 weekly vitamin c infusion - RNA-expression change prostatic tumor tissue 12 20 weekly vitamin c infusion - RNA-expression change lymphocytes 12 20 weekly vitamin c infusion Tertiary endpoint : - Pharmacokinetics vitamin c elderly cancer patient Methods material : - 80 subject include ( efficacy evaluation 20 subject evaluate extension arm ) - Each subject receive weekly infusion 60 gram vitamin c ( form ascorbate ) 12 20 week</brief_summary>
	<brief_title>Vitamin C Anti-cancer Drug</brief_title>
	<detailed_description>Vitamin C palliative treatment : Intravenous vitamin C use since 1970 's terminally ill cancer patient claim big increase survival time . The efficacy drug question randomize , control trial Vitamin C 's efficacy cancer patient survival make . Recent result vitro xenograft study mice show promise vitamin c cytotoxic agent cancer cell . The following parameter record baseline : - Biomarkers ( PSA , bALP , NTX , PINP ) - Routine blood work ( hgb , creatinine , p-vitamin c etc . ) - Radio nucleotide bone scintigraphy - Prostate biopsy later microarray ( Affymetrix ST1.0 ) - Urine sample 8-oxo-guanine ( oxidative DNA-damage measurement ) These parameter repeat treatment , usually 12 26 week first vitamin c infusion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Castration resistant metastatic prostate cancer ( bony visceral metastasis ) Gleason sum &gt; 6 PSA &gt; 10 ng/ml ECOG &lt; 3 Prior orchidectomy LHRH antagonist/agonist treatment Must give informed content Synchronous active cancer ( skin cancer exclude ) Prior chemotherapy History oxalate renal stone Glucose6phosphate dehydrogenase deficiency Impaired renal function ( creatinine &gt; 200micromoles/L Haemochromatosis Cardiac disease ( NYHA &gt; 2 , CSS &gt; 2 , recent AMI ( less 6 month ) Recent major surgery ( le 4 week inclusion 2 day admittance time ) Prior intend curative treatment prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>palliative care</keyword>
	<keyword>antioxidant</keyword>
	<keyword>ascorbic acid</keyword>
	<keyword>rna expression</keyword>
</DOC>